Jeffrey Hung

Mark Breidenbach

Michael Schmidt

Michael Yee

Swapnil Malekar

Yaron Werber

- Immuneering Corporation (IMRX) has entered into a **clinical supply agreement** with Eli Lilly and Company (LLY) for Lilly's second-generation KRAS G12C inhibitor, **olomorasib**.  **[1790340_078a16007e8c4c459ebac17817f15115_0]** 
- This agreement supports a planned **Phase 2 clinical trial** evaluating Immuneering’s lead product candidate, **atebimetinib**, in combination with olomorasib for patients with advanced KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.  **[1790340_078a16007e8c4c459ebac17817f15115_0]** 
- The collaboration aims to achieve a **vertical blockade of the RAS-MAPK pathway**, with preclinical studies of this combination showing enhanced tumor regression and prolonged survival.  **[1790340_078a16007e8c4c459ebac17817f15115_0]** 
- This marks Immuneering's **second collaboration this year** for atebimetinib in NSCLC, following a February 2025 agreement with Regeneron Pharmaceuticals.  **[1790340_078a16007e8c4c459ebac17817f15115_0]**

Immuneering (IMRX)